Translate Bio (TBIO: NASDAQ) Investor Relations Material

Overview

Telesis Bio, a pioneering synthetic biology company, is making waves in the global marketplace with its wide range of synthetic biology instruments, reagents, and associated products and services particularly to pharmaceutical and academic laboratories worldwide. With a focus on delivering integrated solutions, Telesis Bio's products and services empower researchers to seamlessly move from a digital DNA sequence to endpoint-ready synthetic DNA. Notable offerings include BioXp system, BioXp portal, BioXp kits, Benchtop reagents, and short oligo ligation assembly enzymatic DNA synthesis designs. By leveraging these technologies, researchers can significantly reduce timelines for constructing synthetic DNA, RNA, and proteins compared to traditional chemical synthesis, paving the way for more efficient and effective development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines. In addition to its core customer base, Telesis Bio also serves government institutions, contract research organizations, and synthetic biology companies. The foundation of Telesis Bio's current success stems from its incorporation in 2011 as Codex DNA, Inc., primarily located in San Diego, California, and its subsequent name change to Telesis Bio in November 2022.